Does the severity of left ventricular systolic dysfunction impact outcomes of Mitraclip therapy: How low is too low?
Percutaneous mitral valve repair for symptomatic severe mitral regurgitation has rapidly evolved as a viable therapeutic option for high-surgical risk patients. Both randomized clinical studies as well as real world registry data have demonstrated significant improvement in severity of MR and clinical outcomes. In carefully selected patients with severely reduced left ventricular systolic function and severe symptomatic MR, Mitraclip therapy seems to show promise.